The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC).
Domenica Lorusso
No relevant relationships to disclose
Giovanni Scambia
No relevant relationships to disclose
Nicoletta Colombo
No relevant relationships to disclose
Nicholas Reed
No relevant relationships to disclose
Carmen Pisano
No relevant relationships to disclose
Rosemary Lord
No relevant relationships to disclose
Giorgia Mangili
No relevant relationships to disclose
Annamaria Mosconi
No relevant relationships to disclose
Francesco Raspagliesi
No relevant relationships to disclose
Antonella Palazzo
No relevant relationships to disclose
Antonino Ditto
No relevant relationships to disclose
Vanda Salutari
No relevant relationships to disclose
Carmine Conte
No relevant relationships to disclose
Giulia Amadio
No relevant relationships to disclose
Antonio Lambiase
Employment or Leadership Position - MolMed
Claudio Bordignon
Employment or Leadership Position - MolMed